Published in Muscle Nerve on June 28, 2013
Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis (2015) 0.86
Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes. Neurology (2016) 0.77
Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects. Drugs Aging (2015) 0.77
Small nerve fiber involvement in CMT1A. Neurology (2014) 0.76
Quality of life in polyneuropathy: association with biomarkers of small fiber impairment. Health Qual Life Outcomes (2015) 0.75
No Fabry Disease in Patients Presenting with Isolated Small Fiber Neuropathy. PLoS One (2016) 0.75
Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial. Trials (2016) 0.75
Clinical Characteristics, Electrophysiology, and Skin Biopsy of 38 Peripheral Neuropathy Cases with Small Fiber Involvement of Various Etiologies. Chin Med J (Engl) (2017) 0.75
A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy. PLoS One (2017) 0.75
Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care (2010) 6.64
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol (2011) 3.53
The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain (2008) 2.74
Predictors of pain relieving response to sympathetic blockade in complex regional pain syndrome type 1. Anesthesiology (2012) 2.15
Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst (2010) 2.08
Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome. Pain Pract (2010) 1.72
Skin biopsy in the management of peripheral neuropathy. Lancet Neurol (2007) 1.69
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol (2010) 1.63
Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients. Hum Mol Genet (2010) 1.61
IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann Neurol (2005) 1.56
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A (2012) 1.50
Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology (2013) 1.48
Revised normative values for grip strength with the Jamar dynamometer. J Peripher Nerv Syst (2011) 1.48
Amyotrophic lateral sclerosis with mutation of the Cu/Zn superoxide dismutase gene (SOD1) in a patient with Down syndrome. Neuromuscul Disord (2007) 1.44
Sensory neuron diseases. Lancet Neurol (2005) 1.26
Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol (2008) 1.21
Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. Nat Rev Neurol (2012) 1.19
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res (2006) 1.15
Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain (2011) 1.09
Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barré syndrome: case report and review of the literature. J Peripher Nerv Syst (2012) 1.06
Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst (2010) 1.06
Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci (2013) 1.04
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis (2012) 1.03
Co-morbidity and visual acuity are risk factors for health-related quality of life decline: five-month follow-up EQ-5D data of visually impaired older patients. Health Qual Life Outcomes (2009) 1.01
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst (2013) 1.00
Small nerve fiber pathology in critical illness. PLoS One (2013) 0.97
Acute isolated ophthalmoplegia with anti-GQ1b antibodies. Neurol Sci (2011) 0.96
The Domain II S4-S5 Linker in Nav1.9: A Missense Mutation Enhances Activation, Impairs Fast Inactivation, and Produces Human Painful Neuropathy. Neuromolecular Med (2015) 0.96
Small fibre neuropathy. Curr Opin Neurol (2012) 0.95
ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging (2012) 0.95
Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson (2012) 0.94
Modifying the Medical Research Council grading system through Rasch analyses. Brain (2011) 0.94
Neuropathy-associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons. Ann Neurol (2012) 0.94
Neuroactive steroids and peripheral neuropathy. Brain Res Rev (2007) 0.94
Small fiber neuropathy in Fabry disease. Mol Genet Metab (2012) 0.93
Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol (2010) 0.92
The role of sodium channels in painful diabetic and idiopathic neuropathy. Curr Diab Rep (2014) 0.92
Nontraumatic headaches in the emergency department: evaluation of a clinical pathway. Headache (2009) 0.91
Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord (2010) 0.91
The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry (2013) 0.91
Mills' syndrome: an Italian case and revision of the literature. Neurol Sci (2012) 0.91
Painful neuropathies: the emerging role of sodium channelopathies. J Peripher Nerv Syst (2014) 0.90
Painful neuropathy in subclinical hypothyroidism: clinical and neuropathological recovery after hormone replacement therapy. Neurol Sci (2009) 0.90
Erythropoietin: not just about erythropoiesis. Lancet (2010) 0.90
Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord (2012) 0.90
Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation. Brain (2012) 0.89
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer (2007) 0.89
Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst (2008) 0.88
Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve (2005) 0.88
Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiol Dis (2009) 0.87
Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiol Aging (2012) 0.87
Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst (2010) 0.86
Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst (2009) 0.86
Primary focal hyperhidrosis in a new family not linked to known loci. Dermatology (2012) 0.85
Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve (2010) 0.85
Outcome measures in Duchenne muscular dystrophy: are we ready for the new therapeutic era? Neuromuscul Disord (2009) 0.84
Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst (2014) 0.84
Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. J Pain (2009) 0.83
Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol (2011) 0.83
Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery. Pain (2011) 0.82
Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy. Diabetes Care (2006) 0.82
Fatigue and daytime sleepiness scale in myotonic dystrophy type 1. Muscle Nerve (2012) 0.81
Hydroxytyrosol attenuates peripheral neuropathy in streptozotocin-induced diabetes in rats. J Agric Food Chem (2012) 0.81
Electroacupuncture is not effective in chronic painful neuropathies. Pain Med (2011) 0.81